No data

PE-22-28

Spadin Analog PE-22-28

Overview

PE-22-28 is a synthetic analog of spadin — a peptide derived from the propeptide of TREK-1 potassium channels — that has demonstrated rapid antidepressant effects in animal models. It is notable for producing antidepressant effects within 24 hours in mouse models compared to the 2-4 week onset required for conventional antidepressants. PE-22-28 represents a novel mechanism for antidepressant action through TREK-1 channel blockade and is an emerging area of peptide psychiatry research.

Mechanism of Action

PE-22-28 works by blocking TREK-1 — a two-pore domain potassium channel expressed in serotonergic neurons of the dorsal raphe nucleus. TREK-1 channel activity normally hyperpolarizes serotonergic neurons reducing their firing rate and serotonin release. By blocking TREK-1 PE-22-28 depolarizes serotonergic neurons increasing their firing rate and serotonin release in projection areas including the hippocampus and prefrontal cortex — brain regions critical for mood regulation. This mechanism is distinct from SSRIs which block serotonin reuptake rather than increasing its release. The rapid onset (24 hours vs 2-4 weeks for SSRIs) is attributed to the immediate neurophysiological effect of increased serotonergic firing compared to the delayed synaptic adaptations required for SSRI efficacy.

Dosage Information

Typical Dose

Research compound — no established human dosing

Frequency

N/A

Anytime

Administration

Intranasal in animal studies

Notes

Currently preclinical research compound. No human clinical trials completed. Significant interest as a rapid-acting antidepressant candidate.

Where does PE-22-28 sit?

See how this peptide compares across all 111 peptides in our database.

Evidence Score

0.07

Clinical trials
0.0035%
Literature
0.0030%
Community
0.0020%
Completeness
0.5015%

Potential Side Effects

No human safety dataResearch compound only

Community Experiences

Share Your Experience

Sign in to track your experience history and vote on others.
Verifying...

No experiences shared yet. Be the first!

Quick Facts

Administration
Intranasal in animal studies
Typical Dose
Research compound — no established human dosing
Frequency
N/A
References
0 curated + 0 from PubMed
Evidence Score
0.1 / 100